Molecular Tumour Profiling for Detection of Biomarkers in Renal Cell Tumours  Kerstin Junker, Jimsgene Sanjmyatav, Joerg Mueller, Thomas Steiner, Heiko Wunderlich, Aliaksei Chyhrai, Rico Pilchowski, Olaf Reichelt, Joerg Schubert  European Urology Supplements  Volume 6, Issue 10, Pages 611-615 (May 2007) DOI: 10.1016/j.eursup.2007.02.005 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 M-FISH on cell nuclei for identification of different RCC subtypes: (a) clear cell RCC: loss of 3p (1 pink signal); (b) papillary RCC: gain of chromosome 7 (3 red signals), gain of chromosome 17 (3 blue signals); (c) chromophobe RCC: loss of chromosome 1 (1 blue signal), loss of chromosome 2 (1 red signal), loss of chromosome 6 (1 green signal); (d) oncocytoma: loss of chromosome 1 (1 blue signal). European Urology Supplements 2007 6, 611-615DOI: (10.1016/j.eursup.2007.02.005) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 Immunochemistry for detection of CD70 in clear-cell renal cell carcinoma (RCC): (a) tumour tissue; (b) normal renal tissue. European Urology Supplements 2007 6, 611-615DOI: (10.1016/j.eursup.2007.02.005) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 3 Quantification of serum amyloid A (SAA) in clear-cell and papillary renal cell carcinoma (RCC), bladder cancer, and prostate cancer patients and control normal sera by enzyme-linked immunosorbent assay (ELISA); only clear-cell RCC serum samples showed increased SAA levels (median: 28.3μg/ml) compared with control samples. European Urology Supplements 2007 6, 611-615DOI: (10.1016/j.eursup.2007.02.005) Copyright © 2007 European Association of Urology Terms and Conditions